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Incorporationt a group of potent intrinsic inhibitors of retroviral replication. Murine APOBEC3
(mA3) is able to inhibit HIV-1, whereas it is inactive against Moloney murine leukemia virus (MLV). In this
work, we present evidence showing that mA3, compared to hA3G, is incorporated inefﬁciently into MLV,
while the abilities of mA3 and hA3G to be packaged into HIV-1 are similar. The nucleocapsid (NC) domain of
HIV-1 is capable of facilitating the interaction of mA3 with HIV-1 Gag, and thereby the incorporation of mA3
into HIV-1. Swapping studies of the NC domains in HIV-1 and MLV indicate that MLV NC domain is
responsible for viral exclusion of mA3, due to its inability to facilitate the mA3/Gag interaction. The
interaction between mA3 and HIV-1 Gag is mediated by the linker region between two zinc coordination
motifs in mA3, similar to what has been found for the incorporation of hA3G into both HIV-1 and MLV. These
results suggest that the interaction between NC domains and the linker regions might represent a common
mechanism for viral incorporation of APOBEC3 proteins, and the inefﬁcient incorporation of endogenous
mA3 appears to be a strategy by which MLV escapes the inhibitory effect of mA3.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe apolipoprotein B editing catalytic complex subunit 3 (APOBEC3)
proteins are potent intrinsic inhibitors of retroviral replication. Seven
members of the APOBEC3 family in human have been so far identiﬁed,
including APOBEC3A–H, all of which contain one or two conserved His-
X-Glu and Cys-X-X-Cys zinc coordination motifs (Jarmuz et al., 2002).
Several APOBEC3 proteins have been shown to inhibit HIV-1 replication,
whereas the best-studied human APOBEC3G (hereafter referred to as
hA3G) appears to display the most potent anti-HIV activity (Cullen,
2006; Dang et al., 2006). The accumulating evidence demonstrates that
APOBEC3 proteins are capable of inhibiting the replication of a wide
variety of retroviruses and non-retroviruses, suggesting that hA3G and
othermembers in this family not only act as anti-HIV cellular factors, but
also represent a novel component of innate immunity to viral infection
(for review see Cullen, 2006).
HIV-1 virions containing hA3G replicate poorly in newly-infected
cells. HIV Gag is responsible for viral incorporation of hA3G through an
interaction between the nucleocapsid (NC) domain of Gag and hA3G,
and this interaction is facilitatedbyRNA (Alce andPopik, 2004; Cenet al.,
2004a; Khan et al., 2005; Schafer et al., 2004; Zennou et al., 2004). HIV-1ical Research, Jewish General
ec, Canada H3T 1E2. Fax: +358
l rights reserved.counteracts hA3G's anti-viral activity with the viral protein Vif (virion
infectivity factor), which binds to hA3G in the cytoplasm, and induce
degradation of hA3G through proteasome-dependent pathway (Stopak
et al., 2003;Yuet al., 2003). ThemechanismbywhichhA3G inhibitsHIV-
1 replication is not well understood yet. Although it has been suggested
that the anti-HIV activity of hA3G may stem from its ability to form dU
by deaminating dC in the viral cDNA produced during HIV-1 reverse
transcription (Mangeat et al., 2003), several lines of evidence indicate
that the deaminase activity of hA3G is not sufﬁcient to explain its anti-
viral activity, and that its inhibitory effects can be exerted in the absence
of observable editing (Chiu et al., 2005; Guo et al., 2006; Newman et al.,
2005) (Bishopet al., 2006) (Rosler et al., 2005; Turelli et al., 2004). Recent
studies have shown that hA3G appears to inhibit reverse transcription
directly, independently of cytidine deamination, through the inhibition
of primer tRNALys3 annealing (Guo et al., 2006) and strand transfer (Li
et al., 2007).
A mouse gene on chromosome 15 encodes murine APOBEC3
(mA3), the sole member of the APOBEC3 family in mice, which shows
amino acid similarity and structural homology with hA3G (Sheehy
et al., 2002; Wedekind et al., 2003). A short form of mA3 is expressed
more broadly than the full-length form in mice, which is derived from
an alternatively spliced mRNA and lacks exon 5 that encodes amino
acids 199 to 232. HIV-1 Vif is unable to prevent the encapsidation of
mA3 into virions, whose packaging results in severe inhibition of HIV-
1 replication (Mariani et al., 2003). mA3 has been shown to inhibit the
replication of mouse mammary tumor virus (MMTV), both in cultured
Fig. 1. The comparison of viral incorporation of mA3 and hA3G. 293T cell (A and B) or NIH3T3 (C and D) were co-transfected with 2 µg of either BH10.Vif- or MLV proviral DNA, and
various amounts of plasmids coding for hA3G ormA3. The plasmids used are listed along the top of each panel and described in the text. 48 h post-transfection, cells and viruses were
puriﬁed, lysed in RIPA buffer, and cellular and viral proteins were analyzed byWestern blots. A and C. Western blots of cell lysates were probed with either anti-HA (upper panel), or
anti-β-actin (lower panel). B and D. Western blots of viral lysates were probed with anti-HA (upper panel) and either anti-p24 for HIV-1 or anti-p30 for MLV (lower panel). E and F.
293T cells were co-transfected with MLV proviral DNA and various amounts of plasmids coding for either hA3G or mA3. The cytoplasmic expression and viral incorporation of hA3G
and mA3 were determined byWestern blots in the cell and viral lysates, which contain equal amount of β-actin or p30, respectively. Results were normalized to those obtained from
the transfection of cells with 3 μg of hA3G, and were graphically shown in E (cells) and F (virions). The ratios of mA3 to hA3G were determined and listed at the top of each column.
G. Infectivity of MLV containing various amount of mA3 or hA3 was determined as described in Experimental methods. The bar graphs in panel E, F and G represent the means of
results of experiments performed at least three times, and the error bars represent standard deviations.
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virus (MLV) is insensitive to mA3 (Harris et al., 2003; Mangeat et al.,
2003;Mariani et al., 2003). As a simple retrovirus,MLVencodes neither
a protein similar toVif, nor an acidic region similar to that located in the
NC domain of HTLV-1, which facilitates viral exclusion of hA3G (Derse
et al., 2007). Therefore, resistance of MLV to mA3 cannot be attributed
to these known mechanisms underlying other virus species' escape
from the innate immunity. Some studies have shown that mA3 is not
incorporated into MLV, probably due to either its proteolysis by MLV
protease, or a failure to interact with MLV Gag (Abudu et al., 2006;
Doehle et al., 2005), while other studies have presented evidence
suggesting that MLV is relatively resistant to the inhibitory effect of
mA3 due to an unknown mechanism (Browne and Littman, 2008;
Mariani et al., 2003).
In this work, we present evidence showing that mA3, compared to
hA3G, is incorporated inefﬁciently into MLV produced from either
human or mouse cell lines. Mutagenesis studies reveal that the NC
domain of HIV-1, but not MLV, is capable of facilitating the interaction
of mA3 with HIV-1 Gag and the incorporation of mA3 into HIV-1.
Moreover, swapping the NC domains between HIV-1 and MLV Gag
switches the abilities of these two viruses to package mA3, indicating
that the MLV NC domain is responsible for viral exclusion of mA3. The
selective viral incorporation of mA3 suggests that the association of
HIV-1 NC with mA3 is not simply mediated by an RNA bridge, butrather involves an RNA-facilitated protein–protein interaction
mediated by the linker region between two zinc coordination motifs
in mA3. These results also suggest that the interaction between NC
domains and the linker regions represent a common mechanism for
viral incorporation of APOBEC3 proteins.
Results
The comparison of viral incorporation of mA3 and hA3G
To assess the ability of mA3 to be packaged into MLV, we have
performed a quantitative comparison of the incorporation of mA3 and
hA3G into MLV and HIV-1, respectively. Since exon5-deleted mA3, the
most abundant form in mice, has been shown to possess similar
structural and functional features as the full-length form (Mariani
et al., 2003), the short form of mA3 was used in these experiments,
unless otherwise speciﬁed. 293T cells were co-transfected with either
HIV-1 or MLV proviral DNA, and 0.5 or 2.0 μg of plasmid coding for
either hA3G or mA3, both of which contain a C-terminal HA tag. The
lysates of transfected cells were analyzed by Western blots (Fig. 1A),
using anti-HA (upper panel) and anti-β-actin (lower panel) antibodies
as probes. Results showed similar expression of hA3G and mA3 in the
cells transfected with the same amounts of coding plasmids. The viral
incorporation of hA3G or mA3 was analyzed by Western blots of viral
Fig. 2. The incorporation of mA3 into wild-type or mutant HIV-1. 293T cells were co-
transfected with 0.5 µg mA3 and various HIV-1 mutant plasmids. The plasmids used
were listed along the top panel and described in the text. A. Western blots of cell lysates
were probedwith either anti-HA (upper panel), or anti-β-actin (lower panel) B.Western
blots of viral or Gag VLP lysates were probed with either anti-HA (upper panel) or anti-
p24 (lower panel).
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for MLV (Fig. 1B). Results showed that mA3 present in MLV is
approximate 11% and 24% of viral hA3G, respectively, when the cells
were transfected with 0.5 or 2.0 μg of either hA3G or mA3 plasmid,
whereas similar amounts of the hA3G andmA3were detected inHIV-1
virions in each case. Consistent with previous reports (Abudu et al.,
2006; Doehle et al., 2005), these data suggest that mA3, relative to
hA3G, is packaged inefﬁciently into MLV, while both mA3 and hA3G
are incorporated into HIV-1 at the similar efﬁciency. We have also
examined incorporation of mA3 and hA3G into MLV expressed in
NIH3T3 mouse cells. The cells were co-transfected with MLV proviral
DNA and either hA3G ormA3 plasmid, andMLV virions were collected
from the supernatant of transfected cells. Western blots of cellular and
viral lysates showed that the amount of mA3 in MLV was signiﬁcantly
less than that of hA3G (Fig. 1D), although both mA3 and hA3G were
expressed at similar levels (Fig. 1C). These results indicate that
inefﬁcient incorporation of mA3 into MLV occurs whether MLV is
expressed in human or mouse cells.
Although both incorporation of hA3G and mA3 into MLV are
correlated to their cellular expression in a dose-dependentmanner, the
magnitude of dose–response formA3 appears to bemore signiﬁcant in
a range of cellular expression that we tested (Fig. 1B, left side). To
further investigate the effect of cellular expression of hA3G and mA3
upon their incorporation into MLV, we have co-transfected 293T cells
with MLV proviral DNA and various amounts of plasmids coding for
either hA3G or mA3. The cytoplasmic expression and viral incorpora-
tion of hA3G and mA3 were determined by Western blots in the
cell and viral lysates, which contain equal amount of β-actin or p30,
respectively. Results were normalized to those obtained from the
transfection of cells with 3 μg of hA3G, and were graphically shown in
Fig. 1E (cells) and 1F (virions). The ratios of mA3 to hA3G were
determined and listed at the top of each column. Results showed that
cellular expression of these two APOBEC3 proteins equally increase,
whereas the relative viral content ofmA3 to hA3G increased from8% to
31%. Similar results were obtained when full-length mA3 was used in
the experiment (data not shown). We next investigated the effect of
increasing viral hA3G and mA3 upon MLV replication, and found that
MLV infectivity was reduced progressively with increasing amounts of
either hA3G or mA3 plasmid used (Fig. 1G), indicating that both anti-
viral activity of hA3G and mA3 are correlated to their incorporation
into MLV in a dose-dependent manner. It should be noted that hA3G
appears to display more potent anti-MLV activity even in the presence
of similar viral content of hA3G and mA3, consistent with previous
study (Browne and Littman, 2008).
As DNA mutators, expression of endogenous hA3G and mA3 are
expected to be tightly regulated. We have determined copy numbers
of hA3G in H9 (a human T-cell line) and mA3G in RAW264.7 (a mouse
macrophage cell line) using real-time ﬂuorescence-monitored RT/PCR
to amplify equal amounts of total cellular RNA, and found that the
amount of mA3 mRNA in RAW264.7 was approximate 1.3 fold greater
than that of hA3G mRNA in H9. Although quantiﬁcation of
endogenous mA3 is currently lacking due to unavailability of antibody
speciﬁc for mA3, similar copy numbers of hA3G and mA3 mRNA
suggest that endogenous mA3 might be expressed at a similar level as
hA3G. Previous studies have demonstrated that expression of hA3G in
293T cells by transient transfection with 1 μg of hA3G plasmid, was
approximate 10 fold greater than endogenous hA3G in H9 (Guo et al.,
2006). Therefore, despite of the observation that improved packaging
of mA3 into MLV was detected in the presence of overexpression of
mA3, inefﬁcient incorporation of limited endogenous mA3 appears to
be a strategy for MLV to escape from the inhibitory effect of mA3.
The NC domain of HIV-1 Gag is required for the viral packaging of mA3
mA3 is efﬁciently incorporated into HIV-1, but not MLV, suggesting
that viral component(s) in HIV-1 responsible for mA3 encapsidationmay be missing or deﬁcient in MLV. To investigate this hypothesis, we
ﬁrst identiﬁed the viral component in HIV-1 required for viral
incorporation of mA3. Wild-type or mutant HIV-1 were produced
from 293T cells expressing HA-tagged mA3, and cellular expression
and viral incorporation of mA3 were analyzed byWestern blots of cell
(Fig. 2A) and viral (Fig. 2B) lysates, respectively. Various mutant forms
of HIV-1 were used. BH10.P- contains an inactive viral protease. BH10.
FS- contains substitution mutations in frame shift sequence and
produce Gag but not Gag-Pol. hGag contains a humanized HIV-1 Gag
gene (i.e., codon usage optimized for translation in mammalian cells
(Huang et al., 2001)), and produces only wild-type HIV-1 Gag and Gag
VLPs (viral-like particles) (Cen et al., 2004b). As shown in Fig. 2B, mA3
were detected in all wild-type and mutant virus and VLPs. This data
demonstrates that the presence of HIV-1 Vif is unable to prevent the
incorporation of mA3 into HIV-1, i.e., the similar viral content of mA3
were detected in both of Vif-positive (lane 1) and Vif-negative HIV-1
(lane 2), consistent with previous observation that mA3 inhibits HIV-1
replication even in the presence of an active HIV-1 Vif. Efﬁcient
incorporation ofmA3 intoGagVLP indicates that Gag alone is sufﬁcient
among the viral proteins for facilitating the incorporation of mA3 into
HIV-1.
We next used a series of HIV-1 Gag deletion constructs (Fig. 3A) to
identify themotif withinGag involved in the incorporation ofmA3 into
viruses. Since most of these mutant Gag molecules are impaired in
their ability to form extracellular particles due to the absence of either
membrane-binding region (Δ1–132) or I (Δ378–500) and L (Δ433–
500) domains, we have investigated the interaction betweenmA3 and
mutant forms of Gag using co-immunoprecipitation to detect
cytoplasmic complexes. 293T cells were co-transfected with mA3
and either wild-type or mutant Gag constructs, and cell lysates were
Fig. 3. The interaction of mA3 with wild-type or mutant Gag in the cell. 293T cells were co-transfected with mA3 expression vector and different plasmids coding for wild-type or
mutant Gag proteins. Interaction between Gag and mA3 was measured by the ability to co-immunoprecipitate these molecules from cell lysate with anti-HA. Panel A graphically
represents the wild-type and mutant Gag variants tested. The top drawing shows the wild-type Gag domains, with numbers representing the amino acid positions. MA, matrix
domain; CA, capsid domain; NC, nucleocapsid; p6, p6 domain. B. Western blots of lysates (left side) of transfected cells were probed with anti-CA (upper panel) or anti-HA (lower
panel). Western blots of anti-HA immunoprecipitates from cell lysates (right side) were probed with anti-CA (upper panel) or anti-HA (lower panel). C. 293Tcells were co-transfected
withmA3 and BH10.FS- or ZWT.P6. plasmid. The plasmids used are listed along the top of each panel and described in the text.Western blots of cell lysates (left side)were probedwith
either anti-HA (upper panel), or anti-β-actin (lower panel). Western blots of viral lysates (right side) were probed with either anti-HA (upper panel) or anti-p24 (lower panel).
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Western blots of cell lysates show that all Gagmutantswere expressed
at similar levels in the cytoplasm (Fig. 3B, left panel). ThenmA3 in each
cell lysate was immunoprecipitated by anti-HA, and the presence of
bothGag andmA3 in the immunoprecipitatewas analyzed byWestern
blotting, as shown in the right side of Fig. 3B, using anti-p24 and anti-
HA, respectively. This result showed that the removal of either N-
terminal MA domain (Δ1–132) or C-terminal p1/p6 domain (Δ433–
500) had no signiﬁcant effect upon the association of Gag with mA3.
However, a C-terminal deletion of Gag, inwhich theNCdomain (Δ378–
500) was removed, abolished the Gag/mA3 interaction. These data
suggest that the NC domain of Gag is required for the interaction
between mA3 and HIV-1 Gag.
The requirement for the NC domain is further shown in Fig. 3C, in
which the NC domain of HIV-1 Gag has been replaced with a yeast
leucine zipper domain to allow for protein/protein interactions
(plasmid ZWt-p6). It has previously been shown that ZWt-p6 can
efﬁciently produce extracellular viruses (Accola et al., 2000). A frame-
shifting defective HIV-1 mutant (BH10.FS-) was used as a control,
which produced wild-type Gag. Western blot analysis showed that
similar amounts of mA3 and Gag were produced in all the cells, and
that the viral content ofmA3 in ZWt-p6 is reduced 90% comparedwith
BH10.FS-. These data demonstrated that while the leucine zipper
motif can functionally replace the NC domain for Gag multimerizationand virus assembly, it cannot replace its ability to facilitate mA3
incorporation.
The NC domain within MLV Gag is the determinant for inefﬁcient
incorporation of mA3 into MLV
We have shown that HIV-1 NC is required for the interaction of
mA3 with HIV-1 Gag and the incorporation of mA3 into HIV-1.
Similarly, mA3 was reported to interact with mouse mammary tumor
virus (MMTV) NC and to be incorporated into MMTV (Okeoma et al.,
2007). These observations suggested that the NC domain of Gag is the
major determinant for viral incorporation of mA3, andMLV NCmay be
deﬁcient to facilitate the encapsidation of mA3. To address the
hypothesis, we used two HIV-1/MLV chimeras described previously
(Berkowitz et al., 1995), in which HIV-1 NC and MLV NC domains have
been swapped, generating an HIV-1 mutant (HIV-MLVNC) containing
the MLV NC domain and a MLV mutant (MLV-HIVNC) containing an
HIV-1 NC domain. 293T cells were co-transfected with wild-type or
mutant forms of proviral DNAs and either hA3G or mA3 plasmid.
Similar cytoplasmic expression of hA3G and mA3 were detected by
Western blots of cell lysates (Fig. 4A). The viral incorporation of hA3G
or mA3 was analyzed byWestern blot of viral lysate probed with anti-
HA and either anti-p24 for HIV-1 and HIV-MLVNC, or anti-p30 for MLV
and MLV-HIVNC (Fig. 4B). It has been reported that both of HIV-
Fig. 4. NC domain in MLV Gag is the determinant for inefﬁcient incorporation of mA3 into MLV. 293T cells were co-transfected with either hA3G or mA3, and HIV-1, MLV or their
mutant plasmid. The plasmids used are listed along the top of each panel and described in the text. A. Western blots of cell lysates were probed with either anti-HA (upper panel), or
anti-β-actin (lower panel). B. Western blots of viral lysates were probed with anti-HA (upper panel) and either anti-p24 for HIV-1 or anti-p30 for MLV (lower panel). C. Western blots
of anti-HA immunoprecipitates from cell lysates were probed with either anti-p24 for HIV-1 or anti-p30 for MLV anti-CA (upper panel), and anti-HA (lower panel).
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probably due to low incorporation of Gag-Pol during viral assembly.
The different pattern of viral proteins from wild-type and these
mutated viruses may result in inaccurate normalization of viral
production. Therefore we added APV, a protease inhibitor that is able
to inactivate both HIV-1 and MLV proteases, into cell culture medium
6 h post-transfection, and produce immature viral particles for wild-
type and mutated HIV-1 or MLV, with the Gag precursor representing
the majority of viral proteins (Fig. 4B). Results showed that replace-
ment of MLV NC domain with HIV-1 NC domain resulted in an
approximate 7 fold increase in the amount of mA3 incorporated into
MLV, whereas the presence of the MLV NC domain in HIV-1 Gag
caused amore than 90% reduction in the viral content of mA3 in HIV-1.
In contrast, exchange of NC domains between HIV-1 and MLV did not
result in any signiﬁcant effect upon the incorporation of hA3G into
either HIV-1 or MLV (right panel). These data indicate that the NC
domain of MLV Gag is the determinant for the inefﬁcient incorpora-
tion of mA3 into MLV, and that this domain appears functionally
equivalent to the HIV-1 NC domain for the viral packaging of hA3G
into either HIV-1 or MLV.
We next investigated whether the failure of the MLV NC domain to
efﬁciently facilitate viral incorporation of mA3 is due to its inability to
mediate the interaction of MLV Gag with mA3. To examine this, we
analyzed the cytoplasmic Gag/mA3 interaction in 293T cells expres-
sing both mA3 and each one of either wild-type or mutated HIV and
MLV described above, using a co-immunoprecipitation assay withanti-HA. The presence of both Gag and mA3 in the immunoprecipitate
was analyzed by Western blotting probed with either anti-p24 for
HIV-1 or anti-p30 for MLV. Results in Fig. 4C showed that replacement
of MLV NC domain with HIV-1 NC domain signiﬁcantly increased the
amount of mA3 in the co-immunoprecipitates, compared with that of
wild-type MLV. In contrast, the presence of MLV NC domain in HIV-1
Gag caused a great reduction in the content of mA3 interacting with
the mutated HIV-1 Gag. This direct correlation between viral
incorporation of mA3 (Fig. 4B) and the interaction of mA3 with Gag
(Fig. 4C) suggests that the failure of the MLV NC domain to facilitate
viral incorporation of mA3 is most likely due to its inability to mediate
the interaction of MLV Gag with mA3. It is also possible that MLV NC
speciﬁcally interferes with association of RNA with mA3, but not hA3,
and thereby inhibits the incorporation of mA3 into MLV, since the
ability of mA3 and hA3G to bind to RNA are required for their virion
encapsidation.
Sequences within APOBEC3 proteins required for their incorporation into
HIV-1 and MLV
MLV is capable of efﬁciently packaging hA3G, but not mA3,
although mA3 can be incorporated into HIV-1. To identify sequence
requirement within hA3G and mA3 for their viral incorporation, we
have constructed a set of mA3/hA3G chimeras containing a C-terminal
HA tag (Fig. 5A). Chimeras 1 to 3 contained increasing lengths of
5' hA3G sequence joined to mA3 sequence, and chimeras 4 to 6
Fig. 5. The incorporation of the mA3/hA3G chimeras into HIV-1 and MLV. 293T cells
were co-transfected with either HIV-1 or MLV proviral DNA, and the plasmid coding
each of the mA3/hA3G chimeras. Panel A graphically represents the mA3/hA3G
chimeras. The open box shows hA3G domains, and the gray box shows mA3 domains,
with numbers representing the amino acid positions, respectively. B. Western blots of
cell lysates were probed with either anti-HA (upper panel), or anti-β-actin (lower
panel). C. Western blots of MLV lysates were probed with either anti-HA (upper panel)
or anti-p30 (lower panel). D. Western blots of HIV-1 lysates were probed with anti-HA
(upper panel) and either anti-p24 (lower panel).
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sequence. Following the co-transfection of 293T cells with either MLV
or HIV-1 proviral DNA, and wild-type or chimeric APOBEC protein
expression vectors, the cytoplasmic expression and viral incorpora-
tion of the different hA3G/mA3 chimeras were determined by Wes-
tern blots. As shown in Fig. 5B, all the hA3G/mA3 chimeras was
expressed at similar levels, but less than either wild-type hA3G or
mA3. For MLV (Fig. 5C), chimera 1 containing the N-terminal 104
amino acids of hA3G, was unable to be packaged into MLV, whereas
chimera 2 and 3, in which the hA3G sequence was extended to amino
acid 155 and 256, respectively, were incorporated. Of the reciprocal
chimeras, chimera 4 containing the N-terminal 113 amino acids of
mA3 was encapsidated into MLV. In contrast, chimera 5 and 6, inwhich the mA3 sequence was extended to amino acid 156 and 255,
respectively, was undetectable in the viral lysate. Taken together,
these results suggested that the replacement of amino acids 113 to 156
of mA3 with amino acids 105–156 of hA3G was able to rescue mA3
incorporation into MLV.
Fig. 5D shows the incorporation of these chimeras into HIV-1. It has
been previously reported that amino acids 104 to 156, the N-terminal
part of linker sequence between two zinc coordination motifs with-
in hA3G, is required and sufﬁcient for its incorporation into HIV-1 (Cen
et al., 2004a). As expected, chimera 2, 3 and 4 containing the hA3G
fragment, were detected in HIV-1 virion. Chimera 1 and 6, but not
chimera 5, was able to be packaged into HIV-1, suggesting that the N-
terminal part of linker sequence between two zinc coordination
motifs in mA3 can not functionally replace the corresponding
fragment in hA3G for their incorporation into HIV-1, and the packa-
ging of mA3 requires its amino acids 157–255, the C-terminal part of
linker region.
Results obtained from the analysis of APOBEC3 chimeras were
further conﬁrmed by an investigation of the effect of truncations of
hA3G and mA3 upon viral incorporation (Figs. 6 and 7). As shown in
Fig. 5C, the replacement of amino acids 113 to 156 of mA3 with amino
acids 105–156 of hA3G was able to rescue mA3 incorporation into
MLV. The interpretation of these data is either that this fragment of
mA3 possesses an inhibitory effect upon its viral encapsidation, or that
amino acid 105–156 of hA3G is responsible for its incorporation into
MLV. To test these two hypotheses, we ﬁrst mapped the motifs within
hA3G required for its incorporation into MLV, using one set of hA3G
truncations to co-transfect 293T cells with MLV proviral DNA. The
hA3Gmutants have been described previously (Cen et al., 2004a), and
are shown graphically in Fig. 6A. MLV were produced from a 293T cell
expressing either one of the hA3G mutants, then the cytoplasmic
expression and viral incorporation of hA3G variants were determined
by Western blots of cell lysates (Fig. 6B, upper two panel) or viral
lysates (lower two panel). Results show that the removal of either the
N-terminal 104 amino acids or the C-terminal 157–384 amino acids
does not result in any signiﬁcant effect upon hA3G incorporation
into MLV, whereas the hA3G truncation missing the N-terminal 156
amino acids lost its ability to be packaged into MLV. This result
indicates that amino acid 104–156 of hA3G is required for its in-
corporation into MLV.
We next tested the incorporation of one set of mA3 truncation
mutants into MLV and HIV-1 (Fig. 7A), all of which expressed similarly
in the 293T cells (Fig. 7B). Results showed that neither of them was
detected in MLV (data not shown), suggesting that amino acids 113
to 156 of mA3 does not possess an inhibitory effect upon its viral
encapsidation, and amino acids 104–156 of hA3G are able to rescue the
incorporation of mA3 into MLV. Western blot of lysates of HIV-1
virions, which produced from 293T cells expressing either one of the
mA3 truncation, showed that N-terminal 112 and the C-terminal 273–
381 amino acids were not required for packaging of mA3 into HIV-1,
whereas the removal of C-terminal 160–381 amino acids abolished its
viral incorporation (Fig. 7C). These data provided further evidence
showing that the C-terminal part of the linker region within mA3
involves its incorporation into HIV-1.
Discussion
mA3 is able to inhibit replication of bothHIV-1 andMMTV,whereas
it appears to be inactive against MLV (Mariani et al., 2003; Okeoma
et al., 2007). The precisemechanismunderlying insensitivity ofMLV to
mA3 is still largely inconclusive. In this work, we have presented
evidence showing that mA3, compared with hA3G, was inefﬁciently
incorporated into MLV, while both of themwere packaged into HIV-1
at the same efﬁciency (Fig. 1B), consistent with previous reports
(Abudu et al., 2006; Doehle et al., 2005). Similar results obtained using
human or mouse cell lines suggest that inefﬁcient incorporation of
Fig. 6. Sequence in hA3G required for its incorporation into MLV. 293T cells were co-transfected with MLV proviral DNA and either wild-type or mutant hA3G. Panel A graphically
represents the wild-type and mutant hA3G variants. The ﬁlled rectangles represent the two catalytic sites in hA3G, and the numbers represent the amino acid positions. B. Western
blots of cell lysates probed with either anti-HA (upper panel), or anti-β-actin (lower panel). C. Western blots of lysates of MLV produced from these cells probed either anti-HA (upper
panel) or anti-p30 (lower panel).
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Moreover, although both viral incorporation of hA3G and mA3 is
correlated to their cellular expression in a dose-dependentmanner, we
found different magnitudes of dose–response for their incorporation
into MLV (Fig. 1C). With increasing amounts (from 0.25 μg to 3 μg)
of both hA3G and mA3 plasmids used to transfect, the relative viralFig. 7. Sequence in mA3 required for its incorporation into HIV-1. 293T cells were co-transfe
represents the wild-type and mutant mA3 variants. The ﬁlled rectangles represent the two
blots of cell lysates probed with either anti-HA (upper panel), or anti-β-actin (lower panel)
(upper panel) or anti-p24 (lower panel).content of mA3 to hA3G increased from 8% to 31%. This observation
may be an explanation for a recent study showing that both mA3 and
hA3G can be packaged efﬁciently into MLV (Browne and Littman,
2008), although we cannot exclude the possibility that the different
experimental approaches from ours used in these studies cause
different results.cted with HIV-1 proviral DNA and either wild-type or mutant mA3. Panel A graphically
catalytic sites in mA3, and the numbers represent the amino acid positions. B. Western
. C. Western blots of lysates of HIV-1 produced from these cells probed either anti-HA
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mA3mRNA in human and mice cell lines, suggesting that endogenous
mA3 might be expressed at similar levels as hA3G. Previous studies
have demonstrated that the expression of hA3G in 293T cells by
transient transfection with hA3G plasmid, was more than 10 fold
greater than the levels of endogenous hA3G found in H9 cells (Guo
et al., 2006). Therefore, despite the fact that substantial amounts of
mA3 can be detected in MLV produced from cells expressing high
levels of mA3, inefﬁcient incorporation of limited endogenous mA3
appears to be a strategy for MLV to escape from the inhibitory effect of
mA3. In addition, MLV has been reported to be partially resistant to
mA3 present in virions through an unknownmechanism (Browne and
Littman, 2008). Consistent with the previous study, we also found
that hA3G appears to display more potent anti-MLV activity even in
the presence of similar viral content of hA3G and mA3 (Fig. 1). It is
possible that MLV has evolved to possess multiple means against anti-
viral activity of mA3.
Previous studies have demonstrated that the NC domains in
various retrovirus species play an important role in the encapsidation
of APOBEC3 protein (Cullen, 2006). We have shown herein that the NC
domain also facilitated packaging of mA3 in HIV-1, suggesting this
domain is a common requirement for incorporation of APOBEC3
proteins into retroviruses. Interestingly, the replacement of the NC
domain in HIV-1 Gag with MLV NC resulted in a signiﬁcant reduction
in the amount of mA3 in both HIV-1 particle as well as coimmuno-
precipitate of HIV-1 Gag, and the presence of HIV-1 NC instead of MLV
NC rescued both the incorporation of mA3 into MLV and mA3/MLV
Gag interaction. This observation indicates that the NC domain is a
major determinant for the exclusion of mA3 in MLV, and suggests that
MLV NC has evolved to be deﬁcient for virion packaging of mA3.
All of hA3G/HIV-1 Gag, hA3G/MLV Gag, and mA3/HIV-1 Gag in-
teractions appear to be RNA-dependent (Doehle et al., 2005),
suggesting that speciﬁc or non-speciﬁc RNA is required for viral
incorporation of hA3G and mA3. Indeed, recent studies show that 7SL
RNA is involved in the packaging of hA3G and hA3F into HIV-1, and
that the replacement of HIV-1 NC with the leucine zipper motif, i.e.,
ZWt-p6, inhibits viral incorporation of both hA3G and 7SL RNA (Wang
et al., 2007). Since both hA3G and NC are RNA-binding proteins
(Berkowitz et al., 1995; Yu et al., 2004), the RNA could simply serve
as a bridge between the proteins, with no speciﬁc protein–protein
interaction required. Consistent with previous reports, we found that
mA3was able to NC-dependently interact with HIV-1 Gag but notMLV
Gag, suggesting that RNA-binding activities of both mA3 and the
NC domain in MLV Gag are insufﬁcient for their interaction and the
incorporation of mA3 into MLV. Furthermore, swapping the NC
domains between HIV-1 and MLV Gag switched the abilities of these
two viruses to package mA3, providing evidence supporting that the
association of hA3G or mA3 with NC does not simply involve a non-
speciﬁc RNA bridge, but rather involves a speciﬁc protein–protein
interaction facilitated by RNA.
The fact that hA3G and mA3 are incorporated into virions with
diverse NC sequences, suggests that some common property of Gag
NC other than sequence similarity is required. This feature could be
common structural motif in NC domains of retroviruses, such as
zinc ﬁnger and basic residue cluster, both of which were reported to
involve either the interaction of hA3G with HIV-1 Gag or incorpora-
tion of hA3G into HIV-1 (Burnett and Spearman, 2007; Guo et al.,
2007; Luo et al., 2004). The mechanism underlying selective pac-
kaging of mA3 between HIV-1 and MLV remains unclear, since
both HIV-1 and MLV NC contain these common motifs described
above. It is noteworthy that NC domains derived from HIV-1 and
MMTV contain two zinc ﬁngers, both of which are able to facilitate
viral incorporation of mA3, whereas MLV NC contains only one.
Therefore, it is possible that dual zinc ﬁngers might be necessary for
themA3/NC interaction, and further studies are needed to address this
question.Mutagenesis analysis in this work revealed that the linker region
between the two zinc coordination motifs in either hA3G or mA3
is involved in their encapsidation into MLV and HIV-1, respectively
(Figs. 5 and 6). Previous works have demonstrated that the linker
sequence is required for the incorporation of hA3G into HIV-1 (Cen
et al., 2004a), and mutations of amino acid residues in this region,
such as R122, Y124 and W127, can ablate its packaging into virions
(Huthoff and Malim, 2007). Therefore, these observations indicate
that an interaction between the linker region and NC might represent
a common mechanism of virion encapsidation of APOBEC3 proteins.
Interestingly, the zinc coordination motifs in APOBEC3 proteins (the
N-terminal one in hA3G and the C-terminal one in mA3) have also
been reported to facilitate incorporation of hA3G and mA3 into HIV-1,
perhaps because of their RNA-binding ability, i.e., mutations in these
domains abolish both RNA-binding abilities and viral incorporation of
hA3G and mA3 (Navarro et al., 2005). Nevertheless, we have herein
shown that the removal of the N-terminal zinc coordination motif
has no effect upon the incorporation of hA3G into MLV, and the N-
terminal mA3 fragment missing the C-terminal zinc coordination
motif still function in HIV-1 encapsidation like full-length mA3
(Fig. 6B), consistent with a recent report that a mA3 fragment
consisting of 1–197 amino acids is packaged into HIV-1 (Okeoma et al.,
2007). Similarly, we have reported previously that removal of either
one of two zinc coordination motifs, or both together, did not affect
the incorporation of the hA3G fragments into HIV-1 (Cen et al., 2004a;
Li et al., 2007). One possible explanation for these disparate results is
that the zinc coordination motif may be involved in the conformation
change of hA3G and mA3 induced by its binding to RNA, to allow for
the speciﬁc protein–protein interaction between their linker regions
and the NC domains of Gag. Removal of the zinc coordination motif
may result in exposure of the linker regions in both hA3G and mA3,
which might therefore be accessible for the interaction with NC
independently of the proposed conformation change. Consistent
with this hypothesis, we have found that the interaction between
hA3G fragment and HIV-1 Gag is resistant to RNase treatment, and
an N-terminal hA3G fragment (amino acids 1–157) containing the
RNA-binding deﬁcient mutation described previously in the N-




SVC21BH10.P- is a simian virus 40-based vector that contains full-
length wild-type HIV-1 proviral DNA containing an inactive viral
protease (D25G), and was a gift from E. Cohen, University of Montreal.
SVC21BH10.FS- contains mutations at the frameshift site, i.e., from
2082-TTTTTT-2087 to 2082-CTTCCT-2087, which prevents frame-
shifting during the translation of Gag protein, and generates viruses
that contain Gag, but not Gag-Pol (Cen et al., 2004b). ZWt-p6 encodes
a full-length HIV-1 genome, in which the nucleocapsid sequence has
been replaced with a yeast leucine zipper domain (Accola et al., 2000).
BH10.Vif- was generated by introducing a stop codon right after ATG
of the Vif reading frame at 5043, using a site-directed mutagenesis Kit
(Stratagene) (Cen et al., 2004a). Plasmid coding for a full-length
Moloney MLV proviral DNA was provided by Alan Rein. Both MLV-
HIVNC and HIV-MLVNC plasmids used in this work were described
previously and provided by Stephen Goff (Berkowitz et al., 1995). The
hGag plasmid, which encodes the HIV-1 Gag sequence, produces
mRNA whose codons have been optimized for mammalian codon
usage, and was a kind gift from G Nabel, NIH (Huang et al., 2001). All
the N- or C-terminally deleted Gag plasmids were constructed using
PCR, as previously described (Cen et al., 2004a).
cDNA fragment coding for hA3G was cloned into the pcDNA3.1 V5/
His A vector (Invitrogen), which expresses wild-type and mutant
77L. Zhang et al. / Virology 378 (2008) 69–78forms of hA3G with a fused HA tag at the C-terminus, as previously
described (Cen et al., 2004a). Plasmids expressing full-length or
exon5-deleted mA3 were provided by Nathaniel Landau. To construct
truncations of mA3, this cDNA coding for each of mA3 fragments was
PCR-ampliﬁed and cloned into the pcDNA3.1 V5/His A vector. The
resulting constructs express HA-tagged wild-type and mutant forms
of mA3. HA-tagged hA3G/mA3 chimeras expressing vectors were
generated by overlapping extension PCR, using hA3G and mA3
expression plasmids as templates.
Cells, transfections, virus puriﬁcation and infectivity assay
HEK-293T cells were grown in complete DMEM plus 10% fetal calf
serum (FCS), 100 U of penicillin and 100 μg of streptomycin per
milliliter. For the production of viruses, HEK-293T cells were
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, Califor-
nia) according to the manufacturer's instructions. Supernatant was
collected 48 h post-transfection. Viruses were collected from culture
medium by centrifugation in a Beckman SW41 rotor at 26,500 rpm for
1 h through 15% sucrose onto a 65% sucrose cushion. The band of
puriﬁed virus was removed and pelleted in 1× TNE in a Beckman SW41
rotor at 40,000 rpm for 1 h.
For MLV infectivity assays, 293T cells were co-transfected with
wild-type MLV proviral DNA and pBABE-Luc- a MLV-derived vector
that contains a ﬁreﬂy luciferase gene (Rulli et al., 2006). The relative
amounts of MLV particles were quantiﬁed by Western blot of viral
lysate probedwith anti-p30. Equal amounts of virus were then used to
infect subconﬂuent NIH-3T3 cells, and infectivity was determined by
measuring luciferase activity in the lysate of infected cells, as pre-
viously described (Rulli et al., 2006).
Protein analysis
Cellular and viral proteins were extracted with RIPA buffer (10 mM
Tris, pH 7.4,100mMNaCl,1% sodium deoxycholate, 0.1% SDS,1% NP40,
2 mg/ml aprotinin, 2 mg/ml leupeptin, 1 mg/ml pepstatin A, and
100 mg/ml PMSF). The cell and viral lysates were analyzed by SDS
PAGE (10% acrylamide), followed by blotting onto nitrocellulose mem-
branes (Amersham Pharmacia). Western blot analysis was performed
using either 300 µg of cellular protein or 10 µg of viral protein, as
determined by the Bradford assay (Bradford, 1976). Western blots
were probed with monoclonal antibodies that are speciﬁcally reactive
with HIV-1 capsid (Zepto Metrocs Inc.), HA (Santa Cruz Biotechnology
Inc.), and β-actin (Sigma), or a polyclonal antibody p30, a kind gift
from Alan Rein. Detection of proteins was performed by enhanced
chemiluminescence (NEN Life Sciences Products), using as secondary
antibodies anti-mouse (for capsid, HA, and β-actin) and anti-rabbit
(for HA and p30), both obtained from Amersham Life Sciences. Bands
in Western blots were quantitated using the ImageJ 1.35 s automated
digitizing system (NIH).
Immunoprecipitation assay
293T cells from 100 mm plates were collected 48 h post-
transfection, and lysed in 500 μl TNT buffer (20 mM Tris–HCl pH 7.5,
200 mM NaCl, 1% Triton X-100). Insoluble material was pelleted at
1800 ×g for 30 min. 500 μg of lysate protein was used for im-
munoprecipitation of each sample, determined by the BioRad assay.
Equal amounts of protein were incubated with 30 μl HA-speciﬁc
antibody for 16 h at 4 °C, followed by the addition of protein A-
Sepharose (Pharmacia) for 2 h. The immunoprecipitate was then
washed three times with TNT buffer and twice with phosphate-
buffered saline (PBS). After the ﬁnal supernatant was removed, 30 μl of
2× sample buffer (120 mM Tris–HCl, pH 6.8, 20% glycerol, 4% SDS, 2%
β-mercaptoethanol, and 0.02% bromphenol blue) was added, and the
precipitate was then boiled for 5 min to release the precipitatedproteins. After microcentrifugation, the resulting supernatant was
analyzed using Western blots.
Quantitation of hA3G and mA3 mRNA
Total cellular RNAwasextractedwith Trizol™ (Invitrogen), and cDNA
was synthesized from 1 μg of total RNA with oligo-dT, using Super-
Script™ II Reverse Transcriptase (Invitrogen) as described previously
(Mariani et al., 2003). The amount of hA3G and mA3 cDNA produced
from an equal amount of total cellular RNAwas determined, using real-
time ﬂuorescence-monitored PCR with pairs of primers speciﬁc for
either hA3G or mA3, as described previously (Mariani et al., 2003).
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